JP2020200352A5 - - Google Patents

Download PDF

Info

Publication number
JP2020200352A5
JP2020200352A5 JP2020161995A JP2020161995A JP2020200352A5 JP 2020200352 A5 JP2020200352 A5 JP 2020200352A5 JP 2020161995 A JP2020161995 A JP 2020161995A JP 2020161995 A JP2020161995 A JP 2020161995A JP 2020200352 A5 JP2020200352 A5 JP 2020200352A5
Authority
JP
Japan
Prior art keywords
composition
subject
use according
apoe4
mmse
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020161995A
Other languages
English (en)
Japanese (ja)
Other versions
JP7128536B2 (ja
JP2020200352A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2020200352A publication Critical patent/JP2020200352A/ja
Publication of JP2020200352A5 publication Critical patent/JP2020200352A5/ja
Priority to JP2022128786A priority Critical patent/JP2022145949A/ja
Application granted granted Critical
Publication of JP7128536B2 publication Critical patent/JP7128536B2/ja
Priority to JP2025023627A priority patent/JP2025065545A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020161995A 2015-09-10 2020-09-28 特定の患者集団において神経変性障害を処置する方法 Active JP7128536B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022128786A JP2022145949A (ja) 2015-09-10 2022-08-12 特定の患者集団において神経変性障害を処置する方法
JP2025023627A JP2025065545A (ja) 2015-09-10 2025-02-17 特定の患者集団において神経変性障害を処置する方法

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201562216404P 2015-09-10 2015-09-10
US62/216,404 2015-09-10
US201662290287P 2016-02-02 2016-02-02
US62/290,287 2016-02-02
US201662302027P 2016-03-01 2016-03-01
US62/302,027 2016-03-01
US201662365809P 2016-07-22 2016-07-22
US62/365,809 2016-07-22

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018512564A Division JP6789579B2 (ja) 2015-09-10 2016-09-09 特定の患者集団において神経変性障害を処置する方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022128786A Division JP2022145949A (ja) 2015-09-10 2022-08-12 特定の患者集団において神経変性障害を処置する方法

Publications (3)

Publication Number Publication Date
JP2020200352A JP2020200352A (ja) 2020-12-17
JP2020200352A5 true JP2020200352A5 (https=) 2021-04-30
JP7128536B2 JP7128536B2 (ja) 2022-08-31

Family

ID=58240195

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018512564A Active JP6789579B2 (ja) 2015-09-10 2016-09-09 特定の患者集団において神経変性障害を処置する方法
JP2020161995A Active JP7128536B2 (ja) 2015-09-10 2020-09-28 特定の患者集団において神経変性障害を処置する方法
JP2022128786A Pending JP2022145949A (ja) 2015-09-10 2022-08-12 特定の患者集団において神経変性障害を処置する方法
JP2025023627A Pending JP2025065545A (ja) 2015-09-10 2025-02-17 特定の患者集団において神経変性障害を処置する方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2018512564A Active JP6789579B2 (ja) 2015-09-10 2016-09-09 特定の患者集団において神経変性障害を処置する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022128786A Pending JP2022145949A (ja) 2015-09-10 2022-08-12 特定の患者集団において神経変性障害を処置する方法
JP2025023627A Pending JP2025065545A (ja) 2015-09-10 2025-02-17 特定の患者集団において神経変性障害を処置する方法

Country Status (21)

Country Link
US (3) US11191742B2 (https=)
EP (2) EP3347002B1 (https=)
JP (4) JP6789579B2 (https=)
KR (2) KR102547164B1 (https=)
CN (3) CN116712422A (https=)
AU (1) AU2016319107B2 (https=)
CA (1) CA2997376C (https=)
DK (1) DK3347002T3 (https=)
ES (1) ES2952727T3 (https=)
FI (1) FI3347002T3 (https=)
HR (1) HRP20230809T1 (https=)
HU (1) HUE062511T2 (https=)
LT (1) LT3347002T (https=)
MD (1) MD3347002T2 (https=)
MX (2) MX392677B (https=)
PL (1) PL3347002T3 (https=)
PT (1) PT3347002T (https=)
RS (1) RS64481B1 (https=)
SI (1) SI3347002T1 (https=)
SM (1) SMT202300250T1 (https=)
WO (1) WO2017044840A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2941415A1 (en) 2014-03-21 2015-09-24 Alzheon, Inc. Methods for treating neurological disorders
FI3347002T3 (fi) * 2015-09-10 2023-08-10 Alzheon Inc Alzheimerin taudin hoitaminen tietyssä potilaspopulaatiossa
CN108623501B (zh) 2017-03-21 2022-04-19 润佳(苏州)医药科技有限公司 同位素富集的3-氨基-1-丙磺酸衍生物及其用途
CN110003058B (zh) 2018-01-04 2022-01-25 润佳(苏州)医药科技有限公司 3-((l-缬氨酰基)氨基)-3,3-二氘-1-丙磺酸晶型、制备方法及用途
IL316611A (en) * 2018-08-01 2024-12-01 Alzheon Inc Sulfopropanoic acid derivatives for treating neurodegenerative disorders
JP7573512B2 (ja) * 2018-08-01 2024-10-25 アルツェオン・インコーポレーテッド 神経変性障害を治療するための方法
CN111170901A (zh) * 2018-11-13 2020-05-19 润佳(苏州)医药科技有限公司 3-((l-缬氨酰基)氨基)-1-丙磺酸晶型、制备方法及其用途
BR112021025504A2 (pt) * 2019-06-17 2022-04-26 Alzheon Inc Métodos para tratar distúrbios neurodegenerativos
CN116059192B (zh) 2019-11-13 2024-10-29 润佳(苏州)医药科技有限公司 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途
MX2024007070A (es) * 2021-12-09 2024-08-22 Alzheon Inc Alz-801 para uso en el tratamiento de la enfermedad de alzheimer.
EP4475831A1 (en) * 2022-02-07 2024-12-18 Alzheon, Inc. Alz-801 for use in treating a covid-19 associated neurological symptom

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
JP3265577B2 (ja) 1992-10-13 2002-03-11 デューク・ユニバーシティ アポリポ蛋白eの4型イソ型の測定法
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US20050142191A1 (en) 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
US20060079578A1 (en) 2003-06-23 2006-04-13 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
WO2005060393A2 (en) 2003-08-11 2005-07-07 California Institute Of Technology Microfluidic large scale integration
CA2611586A1 (en) * 2005-04-12 2007-06-21 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
PT2089417E (pt) 2006-10-12 2015-04-14 Bhi Ltd Partnership Métodos, compostos, composições e veículos para administrar o ácido 3-amino-1-propanossulfónico
CN102838532A (zh) 2006-11-24 2012-12-26 Ac免疫有限公司 用于治疗与淀粉样物质或淀粉样蛋白有关的疾病的吡唑胺和噻唑胺衍生物
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
US20120009125A1 (en) 2010-07-06 2012-01-12 Lombard Jay L Apoe4 and apoj biomarker-based prevention and treatment of dementia
JP6250394B2 (ja) 2010-08-19 2017-12-20 バック・インスティテュート・フォー・リサーチ・オン・エイジング 軽度の認知障害(mci)および関連障害の処置方法
EP2847218A4 (en) * 2012-05-08 2015-12-30 Univ Ramot APOE4 ANTIBODY FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
LT2994160T (lt) * 2013-05-06 2019-08-26 Baxalta Incorporated Alzheimerio ligos pogrupių gydymas su iš kelių donorų sumaišytu imunoglobulinu g
RU2724190C2 (ru) * 2014-02-08 2020-06-23 Дженентек, Инк. Способы лечения болезни альцгеймера
CA2941415A1 (en) * 2014-03-21 2015-09-24 Alzheon, Inc. Methods for treating neurological disorders
FI3347002T3 (fi) * 2015-09-10 2023-08-10 Alzheon Inc Alzheimerin taudin hoitaminen tietyssä potilaspopulaatiossa

Similar Documents

Publication Publication Date Title
JP2020200352A5 (https=)
KR102795284B1 (ko) 베타-히드록시부티레이트 및 부탄디올의 s-거울상이성질체 및 이의 사용 방법
Healy et al. An association between recurrent oro‐genital ulceration and non‐steroidal anti‐inflammatory drugs
CN100528151C (zh) 莫达非尼药物剂型
JP2018526407A5 (https=)
PL203216B1 (pl) Zastosowanie lecznicze hydroksyetylorutozydów, kompozycja farmaceutyczna zawierająca hydroksyetylorutozydy oraz sól Zn²⁺ i/lub kompleks Zn²⁺, zestaw zawierający hydroksyetylorutozydy oraz sól Zn²⁺ i/lub kompleks Zn²⁺, oraz zastosowanie lecznicze kompozycji farmaceutycznej lub zestawu zawierającego hydroksyetylorutozydy oraz sól Zn²⁺ i/lub kompleks Zn²⁺
FI3347002T3 (fi) Alzheimerin taudin hoitaminen tietyssä potilaspopulaatiossa
JP2020535227A5 (https=)
US10456393B2 (en) Treating pain in patients with hepatic impairment
BR112020008128A2 (pt) comprimidos de liberação retardada de deferiprona e métodos para utilização dos mesmos
US20100035927A1 (en) Medicament for prophylactic and/or therapeutic treatment of alzheimer-type dementia
JP2025111439A (ja) トラピジルを使用した認知障害の治療
WO2009123206A1 (ja) 経口医薬組成物
Smith et al. Lesch-Nyhan syndrome: a case report
JP2015521647A5 (https=)
RU2237475C1 (ru) Комбинированный препарат для устранения симптомов простудных заболеваний и гриппа (варианты)
JP2002348240A (ja) 医薬組成物
CN115607545B (zh) 依达拉奉在自闭症谱系障碍治疗中的应用
JP2012031141A (ja) 骨髄異形性症候群を治療するための組成物および方法
JP3502951B2 (ja) 高脂血症治療剤
JP7291380B2 (ja) 鼻水又は鼻づまりの口腔粘膜投与用即効性改善剤
EP2184284B1 (en) Preventive, inhibitor or remedy for cerebral aneurysm comprising ibudilast as an active ingredient
WO2018192469A1 (en) Inhibitors of fabp4 and methods of treating arthritis
JP2004002362A (ja) くしゃみ抑制組成物
US20110301199A1 (en) Compositions and methods for treating myelodysplastic syndrome